中药复方对不同分子分型乳腺癌患者无病生存率及总生存率的影响

Effect of Chinese Compound Formula on DFS and OS in Breast Cancer Patients with Different Molecular Classification

目的:探讨"乳癌术后方"对不同分子分型乳腺癌患者5年无病生存率(DFS)及总生存率(OS)的影响。方法:观察2000年1月—2008年12月手术的545例乳腺癌患者,免疫组化明确ER、PR、HER2表达情况,并分为luminal型、Her-2过表达型及三阴性。中药组患者均于术后1年内开始服用"乳癌术后方"超过1年;对照组患者未曾服用中药治疗。结果:中药组各分子分型乳腺癌患者无病生存率虽均高于对照组乳腺癌生存期,但并无统计学差异,但中药可延长luminal型和三阴性乳腺癌患者的总生存率,luminal型的死亡风险可降低19.7%,三阴性的死亡风险可降低9.2%。结论:"乳癌术后方"能提高luminal型和三阴性乳腺癌患者5年的总生存率,延长乳腺癌患者的生存期。

Objective:To observe the effect of Ru'ai Shuhou formula(RSR)on five-year disease free survival(DFS)and five-year overall survival(OS)in breast cancer patients with different molecular classification.Methods:545breast cancer patients who operated from January2000to December2008were included in the study.Molecular sub-types were classified by the expressions of ER,PR and HER2with immunohistochemistry method,thus the patients were divided into Luminal type,Her-2positive type and Triple negative type.The patients in the TCM group had been treated with RSR more than one year started within one year after mastectomy.The patients in the control group were never treated with Chinese medication.Results:DSF was higher in the TCM group than that in the control group,but there was no significant difference between the two groups.However,the TCM group could increase OS of the breast cancer patients of Luminal type and Triple negative type; with TCM medication,mortality risk rate was reduced by19.7%for Luminal type,and9.2%for Triple negative type.Conclusion:RSR can improve5-year OS in the patients of Luminal type or Triple negative type,prolong their survival time.